The consensus price target for CRISPR Therapeutics AG (NASDAQ:CRSP) has been adjusted from $72.75 to $65, reflecting changes in financial performance and industry developments. Despite a quarterly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback